Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance.
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance.
复制标题
DOI：
10.1002/alz.12787
复制
发表时间：
2023-04
影响因子：
14
通讯作者：
Hansson, Oskar
中科院分区：
文献类型：
--
作者：
Binette, Alexa Pichet;Janelidze, Shorena;Cullen, Nicholas;Dage, Jeffrey L.;Bateman, Randall J.;Zetterberg, Henrik;Blennow, Kaj;Stomrud, Erik;Mattsson-Carlgren, Niklas;Hansson, Oskar
血浆生物标志物可能会彻底改变全球阿尔茨海默病（AD）的诊断工作。在广泛使用之前，我们需要确定混杂因素是否会影响这些生物标志物的水平及其临床效用。纳入了具有血浆和CSF生物标志物、肌酐、体重指数（BMI）和病史数据的受试者（BioFINDER-1：n=748，BioFINDER-2：n=421）。我们测量了β-淀粉样蛋白（Aβ42，Aβ40），磷酸化tau蛋白（p-tau 217，p-tau 181），神经丝光（NfL）和胶质细胞酸性蛋白（GFAP）。在两个队列中，肌酐和BMI是与NfL、GFAP相关的主要因素，并且在较小程度上与p-tau相关。然而，BMI和肌酐的调整在预测CSF中相应水平或随后痴呆发展的模型中仅具有较小的影响。肌酐和BMI与某些血浆生物标志物水平相关，但对绝大多数个体没有临床相关的混杂效应。
Plasma biomarkers will likely revolutionize the diagnostic work-up of Alzheimer’s disease (AD) globally. Before widespread use, we need to determine if confounding factors affect the levels of these biomarkers, and their clinical utility. Participants with plasma and CSF biomarkers, creatinine, body mass index (BMI), and medical history data were included (BioFINDER-1: n=748, BioFINDER-2: n=421). We measured beta-amyloid (Aβ42, Aβ40), phosphorylated tau (p-tau217, p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). In both cohorts, creatinine and BMI were the main factors associated with NfL, GFAP, and to a lesser extent with p-tau. However, adjustment for BMI and creatinine had only minor effects in models predicting either the corresponding levels in CSF or subsequent development of dementia. Creatinine and BMI are related to certain plasma biomarkers levels, but they do not have clinically relevant confounding effects for the vast majority of individuals.
登录
查看更多内容
DOI：
10.1056/nejmoa1114248
发表时间：
2012-07-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
Inker LA;Schmid CH;Tighiouart H;Eckfeldt JH;Feldman HI;Greene T;Kusek JW;Manzi J;Van Lente F;Zhang YL;Coresh J;Levey AS;CKD-EPI Investigators
通讯作者：
CKD-EPI Investigators
影响因子：
16.6
作者：
Ashton NJ;Janelidze S;Al Khleifat A;Leuzy A;van der Ende EL;Karikari TK;Benedet AL;Pascoal TA;Lleó A;Parnetti L;Galimberti D;Bonanni L;Pilotto A;Padovani A;Lycke J;Novakova L;Axelsson M;Velayudhan L;Rabinovici GD;Miller B;Pariante C;Nikkheslat N;Resnick SM;Thambisetty M;Schöll M;Fernández-Eulate G;Gil-Bea FJ;López de Munain A;Al-Chalabi A;Rosa-Neto P;Strydom A;Svenningsson P;Stomrud E;Santillo A;Aarsland D;van Swieten JC;Palmqvist S;Zetterberg H;Blennow K;Hye A;Hansson O
通讯作者：
Hansson O
影响因子：
11.1
作者：
Mattsson-Carlgren N;Janelidze S;Bateman RJ;Smith R;Stomrud E;Serrano GE;Reiman EM;Palmqvist S;Dage JL;Beach TG;Hansson O
通讯作者：
Hansson O
DOI：
10.1186/s13195-021-00804-9
发表时间：
2021-03-27
期刊：
Alzheimer's research & therapy
影响因子：
--
作者：
Cicognola C;Janelidze S;Hertze J;Zetterberg H;Blennow K;Mattsson-Carlgren N;Hansson O
通讯作者：
Hansson O
DOI：
10.1016/j.jalz.2018.01.010
发表时间：
2018-11
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Hansson O;Seibyl J;Stomrud E;Zetterberg H;Trojanowski JQ;Bittner T;Lifke V;Corradini V;Eichenlaub U;Batrla R;Buck K;Zink K;Rabe C;Blennow K;Shaw LM;Swedish BioFINDER study group;Alzheimer's Disease Neuroimaging Initiative
通讯作者：
Alzheimer's Disease Neuroimaging Initiative